Pliant Therapeutics, Inc. (PLRX)

Market Cap	68.21M -89.5%
Revenue (ttm)	n/a
Net Income	-175.50M
EPS	-2.87
Shares Out	61.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	863,834
Open	1.140
Previous Close	1.130
Day's Range	1.110 - 1.170
52-Week Range	1.090 - 3.780
Beta	1.35
Analysts	Hold
Price Target	3.75 (+237.84%)
Earnings Date	Mar 2, 2026

About PLRX

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 171
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX
• Website: https://pliantrx.com

Analyst Summary

According to 9 analysts, the average rating for PLRX stock is "Hold." The 12-month stock price target is $3.75, which is an increase of 237.84% from the latest price.

Price Target

$3.75

(237.84% upside)

Analyst Consensus: Hold